tradingkey.logo

Precipio Inc

PRPO
View Detailed Chart

16.690USD

-0.880-5.01%
Close 09/19, 16:00ETQuotes delayed by 15 min
25.31MMarket Cap
LossP/E TTM

Precipio Inc

16.690

-0.880-5.01%
Intraday
1m
30m
1h
D
W
M
D

Today

-5.01%

5 Days

-14.41%

1 Month

+16.71%

6 Months

+134.02%

Year to Date

+201.27%

1 Year

+166.27%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
147 / 207
Overall Ranking
438 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 96.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.53M.
Undervalued
The company’s latest PE is -14.13, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 319.42K shares, increasing 6.80% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 17.64K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.14.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Ticker SymbolPRPO
CompanyPrecipio Inc
CEOMr. Ilan Danieli
Websitehttps://www.precipiodx.com/
KeyAI